Cargando…

Systems biology approaches based discovery of a small molecule inhibitor targeting both c-Met/PARP-1 and inducing cell death in breast cancer

Breast cancer is the second most common types of cancer worldwide. Molecular strategies have developed rapidly; however, novel treatments strategies with high efficacy and lower toxicity are still urgently demanded. Notably, biological networks estimated from microarray data and functional activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Tian, Cheng, Lijia, Yan, Xueling, Xiong, Hang, Chen, Jie, He, Gang, Zhou, Hui, Dong, Hongbo, Xu, Guangya, Tang, Yong, Shi, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065998/ https://www.ncbi.nlm.nih.gov/pubmed/32201536 http://dx.doi.org/10.7150/jca.40758

Ejemplares similares

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
por: Du, Yi, et al.
Publicado: (2016)

Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
por: D’Ambrosio, Concetta, et al.
Publicado: (2022)

Inhibition of c‐MET increases the antitumour activity of PARP inhibitors in gastric cancer models
por: Koustas, Evangelos, et al.
Publicado: (2020)

PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities
por: Đukić, Nina, et al.
Publicado: (2023)

In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2021)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Discovery and Computational Analyses of Novel Small Molecule Zika Virus Inhibitors
por: Zhu, Siyu, et al.
Publicado: (2019)

Discovery and characterization of small molecule Rac1 inhibitors
por: Arnst, Jamie L., et al.
Publicado: (2017)

Discovery of Small Molecule Inhibitors Targeting the Sonic Hedgehog
por: Yun, Taikangxiang, et al.
Publicado: (2020)

Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors
por: Liu, Qiang, et al.
Publicado: (2012)

Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors
por: Nishio, Makoto, et al.
Publicado: (2022)

Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase
por: Xu, Tian-Ying, et al.
Publicado: (2015)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

Discovery of METTL3 Small Molecule Inhibitors by Virtual Screening of Natural Products
por: Du, Yue, et al.
Publicado: (2022)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
por: Zhang, Qian, et al.
Publicado: (2020)

The PARP inhibitor ABT-888 potentiates darbazine-induced cell death in carcinoids
por: Somnay, Yash, et al.
Publicado: (2016)

Structure-Based Discovery of Small Molecule Inhibitors of Cariogenic Virulence
por: Zhang, Qiong, et al.
Publicado: (2017)

Discovery of Sulfated Small Molecule Inhibitors of Matrix Metalloproteinase-8
por: Morla, Shravan, et al.
Publicado: (2020)

Discovery of Small-Molecule Allosteric Inhibitors of PfATC as Antimalarials
por: Wang, Chao, et al.
Publicado: (2022)

PARP inhibitors in gastric cancer: beacon of hope
por: Wang, Yali, et al.
Publicado: (2021)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor
por: Michaelides, Iacovos N., et al.
Publicado: (2023)

Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors
por: Al-Sanea, Mohammad M., et al.
Publicado: (2022)

Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma
por: Liu, He, et al.
Publicado: (2023)

Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery
por: Li, Qingxin, et al.
Publicado: (2020)

Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274
por: Hou, Jinxuan, et al.
Publicado: (2011)

Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules
por: Matsuno, Yusuke, et al.
Publicado: (2018)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma
por: Ge, Yang, et al.
Publicado: (2022)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Dual Inhibitors of PARPs and ROCKs
por: Antolín, Albert A., et al.
Publicado: (2018)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

Discovery of an NAD(+) analogue with enhanced specificity for PARP1
por: Zhang, Xiao-Nan, et al.
Publicado: (2022)

Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase
por: Choi, Eungi, et al.
Publicado: (2018)

Discovery and characterization of a small‐molecule enteropeptidase inhibitor, SCO‐792
por: Sasaki, Masako, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m84vkd9bjqrbtafchuhmp35n3a